期刊文献+

四妙散加减为主治疗痛风性关节炎40例 被引量:7

Treating of 40 cases of gouty arthritis by Simiao powder
暂未订购
导出
摘要 目的:观察四妙散加减为主治疗痛风性关节炎的临床疗效。方法:80例符合纳入标准的患者随机分为四妙散加减为主治疗组(治疗组)和秋水仙碱治疗组(对照组)各40例,均连续治疗2周,观察主要症状红、肿、热、痛的改善情况和不良反应发生率。结果:治疗组总有效率达95.0%,对照组为92.5%,两组疗效差异没有统计学意义(P>0.05);两组患者治疗后症状积分均有所下降,较治疗前差异均具有统计学意义(▲P<0.05);且治疗后治疗组的症状积分低于对照组,差异具有统计学意义(★P<0.05);两组患者治疗期间不良反应发生率分别为7.5%(治疗组)和25.0%(对照组),治疗组发生率低于对照组,差异具有统计学意义(P<0.05)。结论:四妙散加减为主治疗痛风性关节炎疗效确切,且减轻了单纯西药治疗的不良反应。 Objective:To observeSimiao powder decoction based treatment of gouty arthritis clinical efficacy.Methods:80 cases met the inclusion criteria were randomly divided intoSimiao powder decoction treatment group(treatment group) and the colchicine treatment group(control group) 40 cases,both continuous treatment for 2 weeks,and the main symptoms of red,swelling,heat,pain and improvement in the incidence of adverse reactions.Results:The total effective rate was 95.0%,92.5% in the control group,differences between two groups was not statistically significant(P0.05);symptom score after treatment,two groups of patients has declined,compared with pre-treatment differences were statistically significance(▲P0.05);and the treatment group,the symptom score than the control group,the difference was statistically significant(★P0.05);two groups of patients the incidence of adverse reactions during treatment were 7.5%(treatment group ) and 25.0%(control group) ,treatment group was lower than the control group,the difference was statistically significant(P0.05) .Conclusion:Simiao powder decoction based treatment of gouty arthritis is effective,and reduce the adverse effects of western medicine alone.
作者 黄松
机构地区 嘉禾县人民医院
出处 《中医临床研究》 2011年第21期12-13,共2页 Clinical Journal Of Chinese Medicine
关键词 痛风性关节炎 四妙散 秋水仙碱 Gouty arthritis Simiao powder Colchicine
  • 相关文献

参考文献3

二级参考文献13

  • 1施桂英.痛风及其药物治疗的策略[J].中华内科杂志,1995,34(2):77-78. 被引量:29
  • 2国家中医药管理局.中医病症诊断治疗标准.南京:南京大学出版社,1994.
  • 3Fessel WJ.Renal outcomes of gout and hyperuricemia.Am J Med,1979,67:74-82.
  • 4Nuki G.Should we treat asymptomatic hyperuricaemia? Ann Rheum Dis,2005,64(Suppl Ⅲ):4.
  • 5Janson RW.Gout.In:West SG,editors.Rheumatology Secrets.Philadelphia:Hanley & Belfus,1997.265-272.
  • 6Wallace SL,Robinson H,Masi AT,et al.Preliminary criteria for the classification of the acute arthritis of primary gouty.In:Klippel JH,editors.Primer on the Rheumatic Diseases.Atlanta:Arthritis Foundation,2001.637.
  • 7Finger DR.Hypouricemic agents and colchicine.In:West SG,editors.Rheumatology Secrets,Philadelphia:Hanley & Belfus,1997.490-495.
  • 8Wallace SL,Singer J.Therapy in gout.Rheum Dis Clin Nor Ame,1988,14:441-457.
  • 9Becker MA,Schumacher HR,Wortmann RL,et al.Febuxostat compared with allopurinol in patients with hyperuricemia and gout.New Engl J Med,2005,353:2450-2461.
  • 10Feher MD,Hepburn AL,Hogarth MB,et al.Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout.Rheumatology,2003,42:321-325.

共引文献60

同被引文献84

引证文献7

二级引证文献88

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部